MOH (Syria)

Syria MoH (Ministry of Health — Syrian Arab Republic) — operating through the Directorate of Pharmaceutical Affairs (DPA) + the Syrian Drug Quality Control & Research Laboratory (SDQC&RL) + the Syrian Pharmacovigilance Centre + the Directorate of Medical Devices + the Directorate of Cosmetics + Dietary Supplements — is the national regulatory authority for human medicines + biologicals + vaccines + medical devices + IVDs + cosmetics + dietary supplements + pharmacy practice + controlled substances across the Syrian Arab Republic. Syria MoH operates under Law 5 of 1990 + Decree 14 of 1971 + Law 2 of 1993 + Ministerial Decisions + DPA Decisions + Guidance Documents.

Syria MoH organisational structure includes:

• Minister of Health — political head appointed by the Council of Ministers.
• Deputy Minister + Director General of the Ministry of Health.
• Directorate of Pharmaceutical Affairs (DPA) — the principal medicines regulator coordinating Drug Registration + Pharmaceutical Inspection + Pricing + Pharmacy Practice + Pharmacovigilance.
• Drug Registration Department — drug + biological + vaccine + biosimilar + generic-medicine registration.
• Pharmaceutical Inspection Department — GMP + GDP + GPP + GVP + GLP inspections of Syrian + foreign manufacturing facilities.
• Pricing Department — Syria operates substantial Ministry-set pharmaceutical pricing including reference-pricing + cost-plus methodology for Syrian-manufactured products + import pricing.
• Directorate of Medical Devices — medical-device + IVD registration + matériovigilance.
• Directorate of Cosmetics + Dietary Supplements — cosmetic-product + dietary-supplement notification.
• Controlled Substances Section — narcotics + psychotropics framework coordination with INCB + Ministry of Interior + Syrian Customs.
• Syrian Drug Quality Control & Research Laboratory (SDQC&RL) — central pharmaceutical QC laboratory; historically a substantial regional capacity.
• Syrian Pharmacovigilance Centre — WHO PIDM-affiliated national PV centre (re-engaging post-conflict).
• International Affairs Section — WHO + Arab League + EMRO + UN-agency coordination.

Syria's distinctive pharmaceutical context: Syria historically operated one of the most substantial Arab-region domestic pharmaceutical-manufacturing industries — ~70+ Syrian-domestic manufacturers (Tamico + Asia + Ibn Hayyan + Alpha + Diamond + Pharex + Medico-Labs + Mediphar + Oubari + Avenzoar + many others) covering ~90% of pre-conflict domestic essential-medicines + generics consumption + substantial pre-conflict Arab + EMRO export presence. The post-2011 conflict + sanctions environment has substantially disrupted this capacity, though substantial domestic manufacturing continues in Government-controlled territory. Foreign manufacturers + sponsors targeting Syria must plan for: substantial sanctions-environment compliance (US Department of the Treasury OFAC + EU Council sanctions + UK OFSI sanctions + humanitarian-exemption General Licenses for medicines + medical devices); substantial UN-agency humanitarian procurement coordination (WHO + UNICEF + UNHCR + UNFPA + UNDP + UNRWA + ICRC + Syrian Arab Red Crescent (SARC) + MSF); substantial cross-border humanitarian operations under UN Security Council Resolution mechanisms (historically via Bab al-Hawa + Bab al-Salam + Al-Yarubiyah + Al-Ramtha border crossings) for North-West Syria + cross-line humanitarian healthcare access; substantial IDP + refugee healthcare commitments (~6+ million internally displaced + ~5+ million refugees in Türkiye + Lebanon + Jordan + Iraq + Egypt + Europe); substantial fragmented territorial governance reality including Government-controlled territory + Autonomous Administration of North and East Syria (AANES) areas + North-West Syria areas.

Syria MoH is distinct from + complementary to: the Syrian Order of Pharmacists (professional licensing body for individual pharmacists); the Syrian pharmaceutical-manufacturing industry historically organised through ~70+ private-sector + State-owned manufacturers; Syrian medical schools + pharmacy faculties (Damascus University + University of Aleppo + Tishreen University + Al-Baath University + Al-Furat University); and substantial UN-agency + NGO humanitarian healthcare operators including WHO + UNICEF + UNHCR + UNFPA + UNDP + UNRWA + ICRC + SARC + MSF + IRC + Première Urgence Internationale + Mercy Corps supporting substantial humanitarian healthcare programmes. Syria's pharmaceutical environment is uniquely characterised by: post-2011 conflict + humanitarian-emergency context; sanctions environment shaping pharmaceutical-import + financial-channel constraints; substantial UN-agency + NGO humanitarian healthcare presence including cross-border operations; historically substantial Syrian-domestic manufacturing capacity rebuilding amid conflict + sanctions; substantial IDP + refugee healthcare commitments; Climate Zone II coastal (Latakia / Tartus) + Climate Zone IVa interior (Damascus / Aleppo / Homs / Hama / Deir ez-Zor) pharmaceutical-stability environment.

Syria MoH is an active League of Arab States Council of Arab Ministers of Health participant + a WHO Eastern Mediterranean Regional Office (EMRO) participant + a WHO PIDM member (re-engaging post-conflict) + maintains operational cooperation channels with WHO + UNICEF + UNHCR + UNFPA + UNDP + UNRWA + ICRC + SARC + MSF for substantial humanitarian healthcare programmes + historically maintained substantial bilateral cooperation with EMA + WHO + Indian CDSCO + Egyptian EDA + Iranian IFDA + Russian Roszdravnadzor reflecting Syria's pharmaceutical-trade relationships.

Syrian pharmaceutical regulation operates under a layered framework of Laws + Ministerial Decisions + DPA Decisions + Guidance Documents:

• Law 5 of 1990 — Pharmacy Practice + Pharmaceutical Establishments framework.
• Decree 14 of 1971 — Pharmaceutical Manufacturing + Local Industry Promotion framework historically central to Syria's substantial domestic manufacturing capacity.
• Law 2 of 1993 — Narcotics + Psychotropics framework substantively aligned with UN Single Convention 1961 + Conventions 1971 + 1988.
• Ministerial Decisions + DPA Decisions on Drug Registration + Medical Devices + Cosmetics + Dietary Supplements + Pricing + Local-Industry-Protection scheduling.
• Syria MoH GMP Guide — substantively aligned with PIC/S GMP Guide + EU GMP + ICH Q7 + WHO TRS 986 Annex 2.
• Syria MoH GDP Guide — substantively aligned with WHO + EU GDP.
• Syria MoH GCP Guide — substantively aligned with ICH E6(R2).
• Syria MoH GVP Guide — substantively aligned with ICH E2 + EU GVP.
• Pharmacopoeia recognition — recognises British Pharmacopoeia + USP + European Pharmacopoeia + Indian Pharmacopoeia + Arab Pharmacopoeia.
• Syrian National Essential Medicines List — substantial framework given Syrian-domestic manufacturer dominance + UN-agency humanitarian procurement.
• Syria MoH Medical Devices framework — Class I-III risk-based classification substantively aligned with EU MDR + GHTF/IMDRF.
• Syria MoH Cosmetics framework — substantively aligned with EU Cosmetics Regulation including INCI ingredient listing + safety substantiation.
• Syria MoH Pricing framework — substantial Ministry-set pricing including reference-pricing + cost-plus methodology for Syrian-manufactured products + import pricing.
• Local-Industry-Protection Scheduling — distinctive framework historically restricting registration of imported products where Syrian-domestic equivalents exist; substantially eroded during conflict but remains structural feature.
• UN-Agency Humanitarian Importation Framework — substantial framework given WHO + UNICEF + UNHCR + UNFPA + UNDP + UNRWA + ICRC + NGO humanitarian-imported medicines + devices for IDP + refugee + vulnerable-population healthcare programmes including cross-border operations.

The Syrian Drug Quality Control & Research Laboratory (SDQC&RL) is Syria MoH's central pharmaceutical quality-control laboratory + has historically been a substantial regional capacity. Syria's substantial Syrian-domestic pharmaceutical-manufacturing industry — historically ~70+ manufacturers covering ~90% of pre-conflict domestic essential-medicines + generics consumption + substantial pre-conflict Arab + EMRO export presence — has been substantially disrupted by the post-2011 conflict + sanctions environment but continues to rebuild in Government-controlled territory.

• ISO/IEC 17025 — SDQC&RL historically pursued ISO/IEC 17025 scope expansion across pharmaceutical chemical + microbiological + biological testing; rebuilding capacity.
• WHO PQ-Lab Aspiration — SDQC&RL historically pursued WHO PQ-Lab designation prior to conflict disruption; would position alongside Saudi SFDA Central Laboratory + Egypt EDA NODCAR + Morocco LNCM + Tunisia LNCM + Jordan JFDA Central Laboratories as WHO-prequalified pharmaceutical QC laboratories in the MENA region.
• Vaccine lot release — SDQC&RL conducts vaccine lot-release testing for Syria MoH + Syrian Expanded Programme on Immunization including UNICEF + WHO + Gavi-supported procurement.
• Pharmaceutical pre-registration + post-market testing — pre-registration quality testing + post-market surveillance + targeted enforcement testing.
• Medical-device + IVD testing — pre-market + post-market quality testing.
• Cosmetic-product + dietary-supplement testing — safety + ingredient compliance testing.
• Counterfeit-medicine forensics — forensic analytical support for Syria MoH + Ministry of Interior + Syrian Customs investigations + WHO Global Surveillance & Monitoring System contributions; substantial reconstruction-era + sanctions-environment + cross-border supply-chain disruption counterfeit risks.
• Capacity-building — historically hosted WHO + Arab League + EMA + USP capacity-building programmes + training for Syrian pharmaceutical analysts.
• GMP Inspectorate support — provides scientific + technical support for Syria MoH Pharmaceutical Inspection Department GMP inspections of Syrian + foreign manufacturing facilities.
• Syrian-domestic manufacturer support — supports historical ~70+ Syrian-domestic manufacturers (Tamico + Asia + Ibn Hayyan + Alpha + Diamond + Pharex + Medico-Labs + Mediphar + Oubari + Avenzoar + many others) rebuilding post-2011 conflict capacity; substantial reconstruction-era technical-assistance role.
• UN-Agency humanitarian medicine quality — distinctive substantial role given substantial UN-agency + NGO humanitarian-procured medicines + reconstruction-era public-health programmes requiring post-market quality verification including cross-border humanitarian operations.

Syria MoH medical-device + IVD regulation operates under Syria MoH Medical Devices framework with Class I-III risk-based classification substantively aligned with EU MDR + GHTF/IMDRF. Foreign manufacturers must appoint a Syrian Authorised Representative. Syria's medical-device market is served by both Syrian-domestic + foreign manufacturers + substantial UN-agency + NGO humanitarian-imported devices for IDP + refugee + vulnerable-population healthcare.

• Risk-based Classification (Class I / IIa / IIb / III) — substantively aligned with EU MDR + GHTF/IMDRF; IVDs classified under separate framework.
• Syrian Authorised Representative — Syria-resident legal entity required for foreign manufacturers; bears post-market vigilance responsibility + Syria MoH regulatory interface.
• ISO 13485:2016 — recognised by Syria MoH as QMS evidence framework; Syria-specific overlay required.
• Reliance pathways — Syria MoH accepts CE Mark + FDA 510(k) + FDA PMA + Health Canada + TGA + Swissmedic + MFDS + Japan-approval evidence as supporting evidence, subject to sanctions-environment compliance for European + UK + US-sourced products.
• Arab League Medical Devices Harmonisation — Syria participates in Council of Arab Ministers of Health medical-device harmonisation.
• UN-Agency Medical Device Humanitarian Importation — substantial framework given WHO + UNICEF + UNHCR + UNFPA + UNDP + UNRWA + ICRC + NGO humanitarian medical-device + IVD importation.
• Post-market vigilance — Syria MoH operates medical-device adverse-event reporting; reporting timelines substantively aligned with IMDRF Adverse Event Reporting Codes.
• IVD Réactovigilance — Syria MoH operates IVD réactovigilance reflecting Syria's clinical-laboratory infrastructure including teaching hospitals + private-sector laboratories + UN-agency-supported field laboratories.
• Cosmetic Notification — cosmetics require Syria MoH Cosmetic Notification + Arabic labelling; INCI-aligned ingredient listing + safety substantiation; substantively EU-aligned framework.
• Dietary Supplement Registration — Syria MoH Dietary Supplements framework; substantively aligned with EU food-supplement framework + Codex Alimentarius.
• Humanitarian Device Importation — substantial UN-agency + NGO humanitarian medical-device + IVD importation framework for IDP + refugee + vulnerable-population healthcare programmes including cross-border operations.
• Importation Permit — Syria MoH Importation Permit required in addition to product registration for foreign-manufactured devices + drugs entering Syria; coordination with Syrian Customs + Ministry of Economy + sanctions-environment financial-channel compliance.

Syria MoH operates the Syrian Pharmacovigilance Centre (SPVC). Syria is a WHO Programme for International Drug Monitoring (PIDM) member + historically contributes ADR data to VigiBase via Uppsala Monitoring Centre (UMC) (re-engaging post-conflict). The SPVC coordinates with university teaching hospitals + private hospitals + UN-agency + NGO humanitarian-healthcare operators. Syria's pharmacovigilance is uniquely shaped by substantial IDP + refugee + vulnerable-population vaccine + essential-medicines safety surveillance commitments + reconstruction-era supply-chain quality risk monitoring + sanctions-environment supply-chain disruption monitoring + substantial counterfeit + substandard medicine surveillance commitments.

• Syrian Pharmacovigilance Centre (SPVC) — coordinated by Syria MoH Directorate of Pharmaceutical Affairs.
• WHO PIDM Member — Syria is a WHO PIDM member; historically contributes ADR data to VigiBase via Uppsala Monitoring Centre; re-engaging post-conflict.
• Syrian PV Network — coordinated national network with effector centres in major Syrian university teaching hospitals (Damascus University Hospital, Tishreen University Hospital — Latakia, University of Aleppo Hospital, Al-Mowasat University Hospital — Damascus, Al-Assad University Hospital — Damascus, Children's University Hospital — Damascus) + Marketing Authorisation Holders + UN-agency humanitarian healthcare operators.
• ADR Reporting — Syria MoH operates ADR reporting via Syria MoH portal; available for healthcare professionals + consumers + Marketing Authorisation Holders.
• E2B(R3) ICSR — Syria MoH accepts E2B(R3) format ICSR submissions substantively aligned with ICH E2B(R3); 15-day SUSAR reporting timeline for clinical trials + post-market.
• PSUR / PBRER — periodic safety update reports substantively aligned with ICH E2C(R2); Syria MoH-specific submission timeline.
• Risk Management Plans (RMP) — Syria MoH requires ICH E2E-aligned Pharmacovigilance Plan + Risk Management Plan for new drugs + biosimilars + vaccines + high-risk products.
• Active surveillance — Syrian PV Centre operates targeted active-surveillance programmes for COVID-19 vaccines + childhood immunisation + oncology + biologicals where capacity permits.
• IDP + refugee + vulnerable-population PV — distinctive substantial commitments for Internally Displaced Persons + vulnerable-population vaccine + essential-medicines safety surveillance coordinated with UNHCR + UNICEF + UNFPA + WHO + UNRWA + SARC + cross-border humanitarian operations.
• AEFI Surveillance — Syrian vaccine adverse-event surveillance aligned with WHO methodology; central to Syrian Expanded Programme on Immunization + UNICEF + Gavi + WHO-supported immunisation campaigns including polio + measles + COVID-19 catch-up campaigns.
• Matériovigilance + Cosmétovigilance — Syria MoH operates parallel matériovigilance for medical devices + cosmétovigilance for cosmetics.
• Counterfeit + substandard medicine surveillance — distinctive substantial role given conflict + sanctions-environment supply-chain disruption + cross-border smuggling + Syria's geographic position creating substantial counterfeit + substandard medicine quality risks.
• Arab League Pharmacovigilance — Syria participates in Arab League Council of Arab Ministers of Health pharmacovigilance harmonisation.

• WHO EMRO Participant — Syria MoH is an active WHO Eastern Mediterranean Regional Office (EMRO) participant; substantial WHO + UN-agency humanitarian healthcare cooperation.
• WHO PIDM Member — Syria historically contributes ADR data to VigiBase via Uppsala Monitoring Centre; re-engaging post-conflict.
• WHO PQ Procurement Recipient — Syria is a substantial WHO + UNICEF + UNHCR + UNFPA + UNRWA + ICRC procurement recipient for humanitarian healthcare programmes; SDQC&RL historically pursued WHO PQ-Lab designation prior to conflict disruption.
• Arab League Council of Arab Ministers of Health Participant — Syria MoH is an active pharmaceutical-harmonisation participant alongside Egyptian EDA + Saudi SFDA + Jordanian JFDA + UAE MoHAP + Lebanese MoPH + Iraq MoH + Morocco DMP + Tunisia DPM/ANPM + Algeria ANPP + Kuwait MoH + Bahrain NHRA + Oman MoH + Qatar MoPH.
• EMA Cooperation — Syria MoH historically maintains EU reliance practice for high-end + biologicals + specialty pharmaceuticals, currently constrained by sanctions environment + humanitarian-exemption General Licenses.
• Indian CDSCO Bilateral — distinctive substantial trade-driven cooperation reflecting India being one of Syria's largest pharmaceutical import sources for products not covered by domestic Syrian manufacturers + sanctions-environment-permitted Indian-CDSCO-approved generics.
• Iranian IFDA Bilateral — substantial trade-driven cooperation reflecting Iran's substantial pharmaceutical export trade with Syria given sanctions-environment-aligned trade relationship.
• Egyptian EDA Bilateral — substantial trade-driven cooperation reflecting Egypt's substantial pharmaceutical export trade with Syria.
• Russian Roszdravnadzor Bilateral — substantial trade-driven cooperation reflecting Russia's substantial pharmaceutical export trade with Syria + Russian biological + vaccine cooperation including Sputnik COVID-19 vaccine.
• PIC/S Cooperation — Syria MoH GMP Guide substantively aligned with PIC/S GMP + EU GMP + ICH Q7; PIC/S dialogue historically maintained.
• ICH Observer Practice — ICH guidelines extensively implemented in Syrian regulatory practice including ICH Q7 + Q8 + Q9 + Q10 + Q11 + E2A-E + M4.
• ICDRA + EMRO participation — historical International Conference of Drug Regulatory Authorities + active WHO EMRO participant.
• UN-Agency Humanitarian Cooperation — substantial cooperation with WHO + UNICEF + UNHCR + UNFPA + UNDP + UNRWA + ICRC + SARC + MSF + IRC + Première Urgence Internationale + Mercy Corps for IDP + refugee + vulnerable-population healthcare programmes; among most substantial UN-agency humanitarian pharmaceutical operational frameworks globally including cross-border operations via Bab al-Hawa + historically other border crossings under UN Security Council Resolution mechanisms.
• Cross-border Humanitarian Operations — substantial cross-border humanitarian operations for North-West Syria + cross-line humanitarian healthcare access via UN Security Council Resolution mechanisms; distinct operational regulatory environment from Syria MoH-governed territory.

• Sanctions-environment compliance missed — most operationally significant feature of Syrian pharmaceutical market access frequently overlooked; foreign manufacturers must comply with US Department of the Treasury OFAC + EU Council sanctions + UK OFSI sanctions + humanitarian-exemption General Licenses for medicines + medical devices; financial-channel compliance particularly central.
• Syrian Authorised Representative not properly designated — application rejected at Syria MoH intake or post-approval compliance failure; Syrian Authorised Representative must be Syria-resident legal entity with appropriate licensure.
• Arabic labelling deficiencies — Arabic required for all-of-Syria market access; many applicants provide insufficient Arabic-language patient leaflet content.
• Syria MoH GMP gaps — applicants assuming EU GMP / PIC/S GMP / FDA GMP compliance is automatically sufficient without addressing Syria-specific Syria MoH GMP clarifications.
• Syria climate-zone stability data missing — Syria is Climate Zone II coastal (Latakia / Tartus) + Climate Zone IVa interior (Damascus / Aleppo / Homs / Hama / Deir ez-Zor) requiring substantial zonal-specific stability data.
• Local-Industry-Protected Status not researched — distinctive Syrian framework historically restricting registration of imported products where Syrian-domestic equivalents exist; foreign-manufactured products may face restricted registration where Syrian-domestic capacity covers the same ATC class; substantially eroded during conflict but remains structural feature.
• Bioequivalence centres + biowaiver — Syria MoH BE Guidance provides BCS-based biowaivers; applicants frequently submit BE studies where biowaivers would suffice.
• WHO PQ-style reliance under-utilised — WHO-PQ-approved products eligible for accelerated Syria MoH review (90-120 day target); under-utilised by many applicants.
• EMA + SRA reliance constrained by sanctions environment — Syria MoH historically operates substantial reliance on EMA + Stringent Regulatory Authority decisions, currently constrained by sanctions-environment compliance for European + UK + US-sourced products.
• Arab League harmonisation not leveraged — Council of Arab Ministers of Health pharmaceutical-harmonisation reliance under-utilised.
• Trade-partner reliance (India CDSCO / Iran IFDA / Egypt EDA / Russia Roszdravnadzor) under-utilised — distinctive substantial trade-driven reliance reflecting Syria's pharmaceutical-import trade relationships given sanctions-environment constraints on European + US sources.
• UN-Agency humanitarian procurement pathway not leveraged — substantial WHO + UNICEF + UNHCR + UNFPA + UNDP + UNRWA + ICRC + SARC humanitarian procurement opportunity for IDP + refugee + vulnerable-population healthcare programmes including cross-border operations frequently overlooked.
• Cross-border humanitarian operations distinct regulatory environment not understood — substantial cross-border humanitarian operations for North-West Syria via UN Security Council Resolution mechanisms operate in distinct operational regulatory environment from Syria MoH-governed territory; substantial coordination with OCHA + WHO + UNICEF + UNHCR + INGO Forum required.
• Essential Medicines + Vital Medicines accelerated pathway not leveraged — accelerated Registration under-utilised; 90-120 calendar day target.
• Syrian-domestic manufacturer partnership opportunities not explored — historical ~70+ Syrian-domestic manufacturers rebuilding post-2011 capacity offer substantial partnership + technology-transfer + contract-manufacturing opportunities; substantially under-utilised by foreign manufacturers.
• Counterfeit + substandard medicine quality risks under-monitored — Syria's conflict + sanctions-environment supply-chain disruption + cross-border smuggling create substantial counterfeit + substandard medicine quality risks requiring substantial post-market quality surveillance frequently overlooked.
• Variations strategy not planned — variations procedure substantively similar to EU but with Syria-specific timelines + fee structure + sanctions-environment administrative delays.
• Registration renewal timing missed — 5-year renewal must be filed within prescribed window before expiry; missed deadline triggers de-registration.

V5 Ultimate provides the operational infrastructure Syrian + foreign-supplier sites need for Law 5 of 1990 + Syria MoH GMP + Medical Devices framework + WHO PQ-style reliance + Arab League + Indian CDSCO + Iranian IFDA + Egyptian EDA + Russian Roszdravnadzor trade-partner reliance + Syrian Pharmacovigilance Centre + UN-agency humanitarian procurement + cross-border humanitarian operations + Syrian-domestic manufacturer rebuild readiness — with built-in sanctions-environment compliance posture.

• Syria MoH GMP control framework — PIC/S + EU GMP + ICH Q7 + WHO TRS 986 Annex 2-aligned controls with ALCOA+ data-integrity + Syria-specific clarifications + Climate Zone II + IVa stability monitoring.
• Syria MoH Registration dossier packaging — Syria CTD-aligned dossier structure with Syria Module 1 specifics + Module 3 stability + Arabic patient leaflet + Authorised Representative declarations + Law 5 of 1990 framework + Local-Industry-Protected Status awareness.
• Sanctions-environment compliance posture — built-in audit-trail evidence for US OFAC + EU + UK OFSI humanitarian-exemption General License coverage + financial-channel compliance documentation + end-user verification packaging.
• WHO PQ-style reliance workflow — WHO-PQ-approved product packaging with reduced dossier + accelerated Syria MoH review (90-120 day target).
• EMA + SRA reliance workflow — Syria MoH-EMA + Syria MoH-Health Canada + TGA + Swissmedic + MHRA + MFDS reliance packaging within sanctions-environment compliance bounds.
• Arab League workflow — Council of Arab Ministers of Health pharmaceutical-harmonisation packaging.
• Trade-partner reliance workflow (India CDSCO / Iran IFDA / Egypt EDA / Russia Roszdravnadzor) — distinctive substantial trade-driven reliance packaging reflecting Syria's substantial pharmaceutical-import trade relationships given sanctions-environment constraints on European + US sources.
• UN-Agency humanitarian procurement workflow — WHO + UNICEF + UNHCR + UNFPA + UNDP + UNRWA + ICRC + SARC humanitarian procurement framework packaging for IDP + refugee + vulnerable-population healthcare programmes including cross-border operations.
• Cross-border humanitarian operations workflow — distinct operational regulatory environment packaging for North-West Syria + cross-line humanitarian healthcare access via UN Security Council Resolution mechanisms + OCHA + WHO + UNICEF + UNHCR + INGO Forum coordination.
• Syrian Authorised Representative workflow — foreign-manufacturer Syrian Authorised Representative designation + role-management + Syria-specific post-market surveillance.
• Syrian-domestic manufacturer rebuild workflow — historical ~70+ Syrian-domestic manufacturer (Tamico + Asia + Ibn Hayyan + Alpha + Diamond + Pharex + Medico-Labs + Mediphar + Oubari + Avenzoar + many others) partnership + technology-transfer + contract-manufacturing packaging supporting post-2011 conflict capacity rebuild.
• Syrian clinical-trial workflow — Syria MoH CTA + Damascus University / University of Aleppo / Tishreen / Al-Baath / Al-Furat IRB coordination + Syrian SUSAR reporting via Syrian Pharmacovigilance Centre.
• Syrian PV Centre integration — E2B(R3) ICSR generation + 15-day SUSAR timeline + PSUR / PBRER packaging + Arabic ICSR + Syrian PV Network coordination + VigiBase upload + Risk Management Plan packaging + AEFI vaccine adverse-event reporting + IDP + vulnerable-population safety surveillance.
• Matériovigilance + Cosmétovigilance workflow — parallel matériovigilance + cosmétovigilance packaging.
• Medical-device + IVD + cosmetic + dietary-supplement workflow — Syria MoH frameworks dossier packaging + Class I-III classification + ISO 13485 + Authorised Representative + post-market vigilance.
• Counterfeit + substandard medicine surveillance workflow — Syria's conflict + sanctions-environment supply-chain disruption + cross-border smuggling monitoring + WHO Global Surveillance & Monitoring System integration.
• Essential Medicines + Vital Medicines accelerated workflow — Syrian National Essential Medicines List + public-health emergency product packaging.
• Arab League + Mashreq + trade-partner regional bridging — for companies operating across Arab League + Mashreq + Indian + Iranian + Egyptian + Russian trade-partner jurisdictions, V5 surfaces Syria MoH + Iraq MoH + Lebanon MoPH + Jordan JFDA + Egyptian EDA + Saudi SFDA + UAE MoHAP + India CDSCO + Iran IFDA + Russia Roszdravnadzor harmonised dossier-element reuse alongside national-specific extensions.